PEB-Pacific Edge

[LoungeLizard]

I'm certainly not complaining about the CR / LCD timing. The record date has passed so no johny-come-lately can pile in on the CR but it does allow long term holders to participate and get a considerable discount in doing so. Quite often CR's have negative effect on holders so it's refreshing that this one delivers an instant windfall.   

[Pierre]

Profit takers moving in now. Will be interesting to see where the SP lands at closing today. Around 25c maybe?

Closed at 27c. A nice 59% gain on the issue price in the CR.

Lots more to come when the LCD is finalised later this year.

Very happy holder here.

[LoungeLizard]

Great day for holders. The negative posts from just a couple of days ago, didn't age well!

Applied for a 20% increase to my holding today - probably will be scaled back. Pretty much a no-brainer to participate in the CR given the 60% discount.

A lot of horse-trading today, but when things settle down I would expect the SP to keep increasing up to the finalisation of the LCD, which is a certainty. Lot's of good news to come - increasing tests and revenues, other providers perhaps coming on board, momentum in Asia and inclusion in the NZX50.
27c is a steal in my opinion given that PEB are in a much stronger position now than they were when the SP was $1.50!

[Greekwatchdog]

Based on todays news, PEB could be a takeover target sooner rather than later. Once the LCD is confirmed in the future PEB has this to themselves as no other product in the LCD

[Left Field]

MFB is in play, whereas PEB is not.
MFB is capable of paying as much as 15% gross dividend in FY28 if a takeover is not forthcoming whereas its anyone's guess when of if PEB might ever pay a dividend.  MFB is much more of heads you win, tails no takeover and with huge dividends in the years ahead you win even bigger.

PEB you are living in hope just like previous shareholders over the decades have lived in hope before you.

What a laugh indeed.

Compare the addressable market for PEB cf MFB.
Compare the protective 'moat' and research that endorses PEB cf MFB.

The market is forward looking.

MFB will never be worth $1b+ with the potential to be worth 2-3x that. Obviously different risk profiles but I'm surprised how many can't see where PEB is not at relative to its past.

Well said.

[Basil]

Imminent commercial success has been promised and inferred many, many times before by PEB management and over more than 2 decades all that's happened is over and over again they keep tapping shareholders for more capital so many times with promises that this time it will be different that I have lost count.  It might take many more years and several more capital raises before this company produces real earnings, if ever.  Good luck to shareholders. 

[Pierre]

I totally understand your perspective Basil; it's a view that is probably shared by all non-shareholders – and perhaps even by a few who are holders.  However, IMO this time IS DIFFERENT.

Last Friday's announcement of a draft LCD for urine-based biomarkers for hematuria evaluation explicitly proposes Medicare coverage for PEB's CxBladder Triage and Triage Plus. This is a hugely significant development, especially when coming so soon after the meeting of a panel of urological experts hosted by Novitas in February.

When the LCD is finalised, potentially later this year, it will provide PEB with access to reimbursement for 66 million Medicare patients. It also will encourage commercial insurers to include coverage in their policies for 223 million lives that they insure. In addition, PEB expects the news to provide a tailwind to the adoption of its products in international markets. As others have alluded to, the addressable market for PEB is enormous and achieving only a relatively small percentage will be a game changer for the business.

Not only does this latest LCD announcement herald a substantial financial opportunity for investors, but also it positions PEB on the international stage to play a significant role in helping to reduce the death rate from the over 600,000 new cases of bladder cancer diagnosed annually worldwide.

Sorry for going on a bit, but I strongly believe PEB is now on the cusp of greatness (and will achieve far more than MFB ever will). The company won't be paying a dividend anytime soon though.

[Poet]

I totally understand your perspective Basil; it's a view that is probably shared by all non-shareholders – and perhaps even by a few who are holders.  However, IMO this time IS DIFFERENT.

Last Friday's announcement of a draft LCD for urine-based biomarkers for hematuria evaluation explicitly proposes Medicare coverage for PEB's CxBladder Triage and Triage Plus. This is a hugely significant development, especially when coming so soon after the meeting of a panel of urological experts hosted by Novitas in February.

When the LCD is finalised, potentially later this year, it will provide PEB with access to reimbursement for 66 million Medicare patients. It also will encourage commercial insurers to include coverage in their policies for 223 million lives that they insure. In addition, PEB expects the news to provide a tailwind to the adoption of its products in international markets. As others have alluded to, the addressable market for PEB is enormous and achieving only a relatively small percentage will be a game changer for the business.

Not only does this latest LCD announcement herald a substantial financial opportunity for investors, but also it positions PEB on the international stage to play a significant role in helping to reduce the death rate from the over 600,000 new cases of bladder cancer diagnosed annually worldwide.

Sorry for going on a bit, but I strongly believe PEB is now on the cusp of greatness (and will achieve far more than MFB ever will). The company won't be paying a dividend anytime soon though.

Fully agree with this and also note that rather than encouraging other non-medicare payers, the law in many states mandates that non-medicare insurers must reimburse these tests once the lcd becomes permanent.
Im very surprised that they are still available at 27c, but maybe their history is dragging on them. They wont be at that price for long imo.